FASEB SRC: The G Protein-coupled Receptor Kinases and Arrestins Conference: Key Modulators of Signal Transduction

项目摘要 G蛋白偶联受体（GPCR）及其下游信号通路对于免疫应答是重要的。 调节许多基本的细胞过程，是一些最常用的处方的目标 药物，如用于治疗疼痛、心力衰竭和高血压的药物（如吗啡、β受体阻滞剂和 血管紧张素抑制剂）。GPCR激酶（GRKs）和抑制蛋白是GPCR的关键调节因子 发信号。它们协同作用，通过降低受体的偶联能力来促进受体脱敏 与G蛋白和靶向活性GPCR进行内吞作用。尽管这些脱敏机制 对于使细胞恢复到其生理静息状态是重要的，GRKs和抑制蛋白也已知 激发非规范信号。在这方面，这些蛋白质在中枢神经系统中起着重要作用， 心血管系统，特别是药物成瘾和心力衰竭等疾病。这 一项提案寻求资助一个论坛，将汇集世界领先的研究人员谁研究不同的 GRK和抑制蛋白生物学方面及其在称为“G蛋白偶联受体激酶”的疾病中的作用 和Arrestins：信号转导的关键调制器。会议将有两大亮点两大基调 演讲者是GPCR、GRK和arrestin结构、功能和细胞生物学方面的专家。此外，高级 初级科学家将能够向该领域的领导者展示他们最新的和未发表的工作， 应该刺激新的假设和方法的产生，并有望导致 这些合作可用于研究和打击药物滥用和心血管疾病。这将是一 学员有很好的机会获得关键的反馈，并建立重要的联系，这将 有利于他们的职业发展。

Project Summary G protein-coupled receptors (GPCRs) and their downstream signaling pathways are important for the regulation of many essential cellular processes and are targets of some of the most commonly prescribed drugs, such as those used to treat pain, heart failure, and high blood pressure (e.g. morphine, β blockers, and angiotensin inhibitors, respectively). GPCR kinases (GRKs) and arrestins are key regulators of GPCR signaling. They act in tandem to promote receptor desensitization by reducing the ability of receptors to couple with G proteins and by targeting active GPCRs for endocytosis. Although these desensitization mechanisms are important for returning cells to their physiological resting states, GRKs and arrestins are also known to instigate non-canonical signaling. In this regard, these proteins play prominent roles in the central nervous and cardiovascular systems, and especially in diseases such as drug addiction and heart failure, respectively. This proposal seeks funding for a forum that would bring together world-leading researchers who study different aspects of GRK and arrestin biology and their roles in disease called "G Protein-Coupled Receptor Kinases and Arrestins: Key Modulators of Signal Transduction". Two major highlights of the meeting will be two keynote lectures who are experts in GPCR, GRK, and arrestin structure, function, and cell biology. In addition, senior and junior scientists will be able to present their most recent and unpublished work to leaders in the field, which should stimulate the generation of new hypotheses and methodologies and hopefully lead to the beginning of collaborations that can be used to study and combat drug abuse and cardiovascular disease. This will be a great opportunity for trainees to get critical feedback and make important connections, which will benefit their career advancement.